Oscar Health initiated with an Underweight at Barclays

Barclays initiated coverage of Oscar Health (OSCR) with an Underweight rating and $17 price target After years of investing in growth, Oscar and new CEO Mark Bertolini laid out “a compelling path” to $2.25-plus in EPS in 2027 at the company’s 2024 investor day, but several new policy risks have emerged since then beyond the expiration of enhanced subsidies, including integrity rules, CSR funding, and pharmacy tariffs, all of which put margin and growth targets at risk, the analyst tells investors.